Descrizione Clinica
Anti-inflammatory Nurofen bb100mg/5ml fever in Nurofen
NUROFEN FEVER AND PAIN CHILDREN 100 MG/5 ML
active ingredients
NUROFEN FEBRUARY AND ONLY Children 100mg/5ml Oral suspension. Each ml of oral suspension contains: Active ingredient: ibuprofene 20 mg. Excipients with known effects: maltitol, glycol propylene and sodium. For the full list of excipients, see paragraph 6.1.Excellent
Nurofen Fever and Pain Children 100mg/5ml oral suspension orange taste without sugar: Polysorbed 80, glycerin, maltitol syrup, sodium saccharin, citric acid, citrate sodium, xanthan gum, chloride sodium, orange aroma, domifen bromide, purified water. Nurofen Fever and Pain Children 100mg/5ml oral suspension Strawberry taste without sugar: Polysorbed 80, glycerin, maltitol syrup, sodium saccharin, citric acid, citrate sodium, xanthan gum, chloride sodium, strawberry aroma, domifen bromide, purified water.Therapeutic indications
Symptomatic treatment of mild or moderate fever and pain.Contraindications
• Hypersensitivity to ibuprofen or any of the excipients listed in the paragraph 6.1. • Children under 3 months or less than 5.6 kg. • The medicinal specialty is contraindicated in patients who show or have previously shown hypersensitivity (e.g. asthma, rhinitis, angioedema or urticaria) to acetylsalicylic acid or other analgesic, antipyretic, non-steroidal anti-inflammatory (NSAID), especially when hypersensitivity is associated with nasal and asthma polypoxes. • Active peptic ulcer. • Severe kidney or liver failure (see paragraph 4.4). • Severe heart failure (see paragraph 4.4). • History of gastrointestinal hemorrhage or perforation, related to previous therapies based on NSAID history of hemorrhage / recurrent peptic ulcer (two or more distinct episodes of proven ulceration or bleeding). • Concurrent use of NSAIDs, including specific COX-2 inhibitors. • During the last quarter of pregnancy (see paragraph 4.6).Population
Posology. The daily dose is structured according to the weight and age of the patient. Undesirable effects can be minimized with the use of the minimum effective dose for the shortest possible treatment duration needed to control symptoms (see paragraph 4.4). In children aged 3 to 6 months limit administration to those weighing more than 5.6 kg. Method of administration: Oral administration to infants and children aged between 3 months and 12 years should take place by means of dosing syringe or dosing spoon provided with the product. Patients suffering from stomach problems can take the medicine during meals. The daily dose of 20-30 mg/kg body weight, divided 3 times a day at intervals of 6-8 hours, can be given on the basis of the following diagram (do not exceed the recommended doses). The graduated scale on the syringe body highlights the heels for different dosages; in particular the 2.5 ml notch corresponding to 50 mg of ibuprofene and the 5 ml notch corresponding to 100 mg of ibuprofene. The dosing teaspoon contains two notches for two different dosages: the 2.5 ml notch corresponding to 50 mg of ibuprofene and the 5 ml notch corresponding to 100 mg of ibuprofene.| Weight | Indicative age | Single dose in ml | maximum number of administrations/day |
| From 5.6 kg | 3 - 6 months | 2.5 ml | 3 in 24 hours |
| From 7 Kg | 6 - 12 months | 2.5 ml | |
| From 10 Kg | 1 - 3 years | 5 ml | |
| From 15 Kg | 4 - 6 years | 7.5 ml (5 ml + 2.5 ml) | |
| From 20 Kg | 7 - 9 years | 10 ml | |
| From 28 to 43 Kg | 10 - 12 years | 15 ml |
Conservation
No Detail.Warnings
Undesirable effects can be minimized with the use of the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see below paragraphs on gastrointestinal and cardiovascular risks). The use of Nurofen Fever and Pain should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs can cause hypersensitivity reactions, potentially serious (anaphylactoid reactions), even in individuals not previously exposed to this type of medication. The risk of hypersensitivity reactions after taking ibuprofen is greater in individuals who have presented such reactions after the use of other analgesic, antipyretic, nonsteroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), nasal polyposi or previous angioedema episodes (see paragraph 4.2 and paragraph 4.8). Gastrointestinal hemorrhage, ulceration and drilling: during treatment with all NSAIDs, at any time, with or without warning symptoms or previous history of serious gastrointestinal events, gastrointestinal hemorrhage, ulceration and perforation, which may be fatal. In dehydrated children and adolescents there is a risk of alteration of kidney function (see paragraph 4.3 and 4.8). Senior patients have an increase in the frequency of adverse reactions to NSAIDs, especially hemorrhages and gastrointestinal perforations, which can be fatal (see paragraph 4.2). In the elderly and in patients with history of ulcer, especially if complicated by hemorrhage or perforation (see paragraph 4.3), the risk of gastrointestinal hemorrhage, ulceration or perforation is higher with increased doses of NSAID. These patients must begin treatment with the lowest dose available. Concurrent use of protective agents (e.g. misoprostol or protonic pump inhibitors) must be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see paragraph 4.5). Patients with history of gastrointestinal toxicity, particularly elderly, must report any unusual gastrointestinal symptoms (especially gastrointestinal hemorrhage) in particular in the early stages of treatment. Caute should be lent to patients taking concomitant medications that could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-aggregating agents such as acetilsalicylic acid (aspirin) (see paragraph 4.5). When hemorrhage or gastrointestinal ulcer occurs in patients taking Nurofen Fever and Pain, treatment should be suspended. NSAIDs should be given with caution to patients with a history of gastrointestinal disease ( ulcerative colitis, Crohn's disease) since such conditions can be exacerbated (see paragraph 4.8). Severe skin reactions some of which fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and epidermal toxic necrolysis, have been reported very rarely in association with the use of NSAIDs (see paragraph 4.8). In the early stages of therapy patients seem to be at higher risk: the onset of reaction occurs in most cases within the first month of treatment. Nurofen Fever and Pain must be stopped at the first appearance of skin rash, mucosa lesions or any other sign of hypersensitivity. The chickenpox can exceptionally be the origin of serious infectious complications to the skin and soft tissues. To date, the contribution of NSAIDs cannot be excluded in the worsening of such infections, therefore it is recommended to avoid the use of Nurofen Fever and Pain in case of chickenpox. Cautisus is required (discussed with your physician or pharmacist) before starting treatment in patients with positive anamnesis for hypertension and/or heart failure because in association with the treatment with the NSAIDs, fluid retention, hypertension and edema were found. Clinical studies and epidemiological data suggest that the use of ibuprofen, especially at high doses (2400 mg/die) and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤ 1200 mg/die) are associated with an increase in the risk of myocardial infarction. Patients with uncontrolled hypertension, congestive heart failure, established ischemic cardiopathy, peripheral arterial disease and/or cerebrovascular disease should be treated with ibuprofen only after careful consideration. Analogue considerations must be made before starting a long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). The use of ibuprofen, acetylsalicylic acid or other analgesic, antipyretic, non-steroidal anti-inflammatory, requires special caution: • in case of asthma or allergic diseases in place or in advance: possible deterioration of bronchoconstriction; • in the presence of clotting defects: reduction of coagulation; • in the presence of kidney, heart or hypertension diseases: possible critical reduction of kidney function (especially in subjects with impaired kidney or liver function, heart failure or in treatment with diuretics), nephrotoxicity or fluid retention; • in the presence of liver diseases: possible hepatotoxicity; • rehydrate the subject before the start and during the treatment in case of dehydration (e.g. for fever, vomiting or diarrhea). The following precautions are relevant during prolonged treatment: • monitor the signs or symptoms of gastrointestinal ulceration or bleeding; • monitor signs or symptoms of hepatotoxicity; • monitor signs or symptoms of nephrotoxicity; • if visual disturbances arise (unused or reduced view, rhytoms, alteration of color perception): stop the treatment and consult the ophthalmologist; • if signs or symptoms of meningitis arise: assess the rare possibility that it is due to the use of ibuprofene (aseptic menus; most frequent in subjects suffering from systemic erythematose lupus and mixed disease of connective tissue or other collagenopathies) (see paragraph 4.8). Since Nurofen Fever and Pain contains maltitol, patients with rare hereditary problems of fructose intolerance should not take this medicine. Nurofen Fever and Pain does not contain sugar and is therefore indicated for those patients who need to control sugar and calorie intake. This medicine contains less than 1 mmol (23 mg) of sodium for doses up to 12 ml, i.e. essentially “without sodium” and about 1.2 mmol (about 27.6 mg) of sodium for each dose of 15 ml. This is equivalent to approximately 1.4% of the maximum daily intake recommended with the diet of an adult. NUROFEN FEBRUARY AND DOLORE Children 100mg/5ml oral suspension Strawberry taste without sugar contains 3.3 mg propylene glycol (present in strawberry aroma) in 1 ml.Interactions
Ibuprofen should be avoided in association with: • Acetylsalicylic acid (aspirin): unless acetylsalicylic acid at low dose (no more than 75 mg per day), as for common clinical practice, has not been recommended by the doctor, since it can increase the risk of adverse reactions (see paragraph 4.4). Experimental data indicates that ibuprofen can inhibit the effects of acetylsalicylic acid at low dose on pyasternic aggregation when drugs are administered in conjunction. However, data evacuity and uncertainty regarding the application of ex-live data to the clinical situation do not allow to draw definitive conclusions on the regular use of ibuprofen; clinically relevant effects are unlikely due to the occasional use of ibuprofen (see paragraph 5.1). • Other NSAIDs included selective cycloxygenase-2 inhibitors: avoid the contemporary use of two or more analgesic, antipyretic, non-steroidal anti-inflammatory drugs: increased risk of side effects (see paragraph 4.4). Ibuprofen should be used with caution in association with: • corticosteroids: increased risk of gastrointestinal ulceration or hemorrhage (see paragraph 4.4); • chinolonic antibiotics: data from animal studies indicate that NSAIDs can increase the risk of convulsions associated with chinolonic antibiotics. Patients taking NSAIDs and Chinoloni may have an increased risk of developing seizures; • anticoagulants, such as warfarin: NSAIDs can increase the effects of anticoagulants (see paragraph 4.4); • Serotonin reuptake selective anti-aggregating agents and inhibitors (SSRIs): increased risk of gastrointestinal hemorrhages (see paragraph 4.4); • anti-diabetics: possible increase in sulfaniluree effect; • antivirals, such as ritonavir: possible increase in the concentration of NSAIDs; • cyclosporin: increased risk of nephrotoxicity;• mifepristone: NSAIDs should not be administered in 8-12 days following mifepristone intake because they can reduce its effectiveness; • cytotoxic, such as methorate: reduction of excretion ( increased risk of toxicity); • lithium: reduction of excretion (increased risk of toxicity); • tacrolimus: increased risk of nephrotoxicity; • uricosuric, as probenecid: slows down the excretion of NSAIDs (increasing plasma concentrations); • metotrexate: potential increase in plasma concentration of metotrexate; • zidovudine: increased risk of blood toxicity when NSAIDs are used in association with zidovudine. There are demonstrations of increased risk of hemartrosis and hematomas in HIV hemophilics (+) if treated simultaneously with zidovudine and ibuprofen; • diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired kidney function (e.g. dehydrated patients or elderly patients with impaired kidney function) co-administration of an inhibitor ACE or an angiotensin II antagonist and agents inhibiting the cyclo-oxidase system can lead to further deterioration of kidney function, which includes a possible acute kidney failure, generally reversible. These interactions must be considered in patients taking Nurofen Fever and Pain in conjunction with ACE inhibitors or antagonists of angiotensin II. Therefore, the combination should be given with caution, especially in elderly patients. Patients should be properly hydrated and monitoring of renal function should be taken into consideration after the start of concomitant therapy and periodically; • cardiac glycosides: NSAIDs can worsen heart failure, reduce VGF (glomerular filtration speed) and increase plasma levels of glycosides.Effects
The list of the following side effects includes all those that were recognized during treatment with ibuprofen for short periods of treatment and for daily doses up to a maximum of 1200 mg. In case of therapies for chronic or prolonged high dose pathologies, other side effects may occur. Adverse reactions associated with the administration of ibuprofen are listed to follow according to the classification for systems and organs and according to the frequency. The frequencies are defined as: Very common (≥1/10); City (≥1/100, ≥1/1.000, ≥1/10.000,Overdosing
Toxicity Signs and symptoms of toxicity were generally not observed at doses less than 100 mg/kg in children or adults. However, in some cases you may need a support treatment. It has been observed that children manifest signs and symptoms of toxicity after ingestion of ibuprofen at doses of 400 mg/kg or greater. The half-life of the drug in case of overdose is 1.5-3 hours. Synonyms Most patients who accidentally ingest clinically relevant amounts of ibuprofen will manifest symptoms within 4-6 hours. The most commonly reported overdose symptoms include: nausea, vomiting, abdominal pain, lethargy and drowsiness. The effects on the central nervous system (SNC) include headaches, tinnitus, dizziness, seizures and loss of consciousness. Rarely, nistagm, metabolic acidosis, hypothermia, kidney effects, gastrointestinal bleeding, coma, apnea, diarrhea and depression of the SNC and respiratory system were also reported. Disorientation, state of excitement, fainting and cardiovascular toxicity including hypotension, bradycardia and tachycardia have been reported. In cases of significant overdose are possible kidney failure and liver damage. In cases of severe poisoning, it is possible that metabolic acidosis occurs and an extension of the protrombine time (INR), probably caused by interference with the action of the factors of the coagulation present in the circle. An exacerbation of the symptoms of the disease can occur in asthmatic subjects. Treatment There is no specific antidote for overdosing ibuprofen. In case of overdose, a symptomatic and support treatment is indicated and must include the maintenance of airway pervity and the monitoring of heart function and vital signs until the patient's stabilization. Particular attention is given to the control of blood pressure, acid-base balance and gastrointestinal bleeding. Within an hour of the ingestion of a potentially toxic quantity, the administration of activated carbon must be taken into account. Alternatively, in the adult, within an hour of the ingestion of a potentially dangerous overdose for life must be taken into account the gastric lavender. An adequate diuresis must be ensured and renal and hepatic functions must be closely monitored. The patient must remain under observation for at least four hours after ingestion of a potentially toxic drug. Any occurrence of frequent or prolonged seizures must be treated with diazepam or lorazepam intravenously. If ibuprofen has already been absorbed, alkaline substances must be administered to promote excretion in the urine of acid ibuprofen. Administer bronchodilators in case of asthma. Other support measures may be required in relation to the patient's clinical conditions. For more information, contact the local anti-veleni center.It is unlikely that subjects under 12 years of age will go to pregnancy, or breast breastfeeding. The following considerations must also be taken into account in such circumstances.
Pregnancy:
During the first and second quarter of pregnancy, the administration of ibuprofen should be avoided. Ibuprofen is contraindicated during the third trimester of pregnancy. Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Results of epidemiological studies suggest an increased risk of abortion and cardiac malformation and gastroschisis after the use of an inhibitor of prostaglandin synthesis in the early stages of pregnancy. The absolute risk of heart failure increased from less than 1% to about 1.5%. It has been considered that the risk increases with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors showed an increase in the loss of pre- and post-plant and embryo-fetal mortality. In addition, an increase in the incidence of various malformations, including cardiovascular disorders, was reported in animals that had been given prostaglandin synthesis inhibitors during the organogenetic period. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: - cardiopulmonary toxicity (with premature closure of arterial duct and pulmonary hypertension); - kidney dysfunction that can progress to kidney failure with oligo-idroamnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of the bleeding time, an anti-aggregating effect that can also be necessary at very low doses; - inhibition of uterine contractions resulting in delay or extension of labor.Nursing:
There are limited data that demonstrates that ibuprofen can go into low concentrations in breast milk and is unlikely to have side effects for infants.Fertility:
Not relevant.Source: Farmadati
